Cyclosporine-a attenuates retinal inflammation by inhibiting HMGB-1 formation in rats with type 2 diabetes mellitus

Peng Wang, Fei Chen and Xuedong Zhang *

Abstract

Background: Cyclosporine-A has been regarded as an immunoregulatory and anti-inflammatory drug for the treatment of various immune inflammatory diseases. However, the effect of Cyclosporine-A on the retina of type 2 diabetic rats and the underlying mechanism remains to be elucidated. The objective of the present study was to investigate the effect and mechanism of Cyclosporine-A on diabetic retinopathy.

Methods: Male Sprague-Dawley rats were established to type 2 diabetic model. After 6 weeks, diabetic rats and normal controls were intravitreally injected with Cs-A (42 ng/2 μL) to the left eye, and 2 μL DMSO to the right eye for the control. Another group of normal wild-type rats was subjected to intravitreal injections into the left eyes with 5 μL PBS or HMGB-1 (5 ng/5 μL) or HMGB-1 (5 ng/5 μL) plus Cs-A (42 ng/2 μL), respectively. Retinal morphological changes were observed with Hematoxylin–eosin staining. Expressions of HMGB-1, IL-1β and TNF-α were detected by immunohistochemistry, ELISA or Western blot or RT-PCR.

Results: Retinal expression levels of IL-1β and TNF-α were upregulated in type 2 diabetic rats and in normal rats with intravitreal injection of HMGB-1, which were attenuated by intravitreal Cs-A. Moreover, Cs-A decreased HMGB-1 expression in diabetic retina and relieved the retinopathy in type 2 diabetic rats.

Conclusions: Intravitreal administration of Cs-A showed a protective effect on retina of diabetic rats, possibly by downregulating retinal expressions of IL-1β and TNF-α via the suppression of HMGB-1.

Keywords: Cyclosporine-a, Diabetic retinopathy, HMGB-1, Inflammation, IL-1β, TNF-α

Background

Diabetic retinopathy (DR) is the most common ocular complication of diabetes mellitus (DM), occurring in more than 60% of patients with type 2 DM [1]. Along with the increasing prevalence of DM worldwide [2], DR is the leading cause of visual impairment and blindness in adults, which results in heavy economic burdens for healthcare systems. The underlying mechanism of DR is intricate and remains incompletely revealed. Mounting evidence suggests that chronic low-grade inflammation is involved in the pathogenesis of DR [3]. In the early stages of DR, expression levels of inflammatory cytokines, namely interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), are elevated in the retina, vitreous and serum of diabetic patients and rodents [4, 5]. Those cytokines are believed to promote leucocyte adhesion and vascular lesions in the retina. In addition, recent studies indicate that high mobility group box-1 (HMGB-1) protein, a proinflammatory mediator, participates in DR via activation of inflammatory cascades [6, 7]. Cyclosporine-A (Cs-A) was firstly used to prevent organ rejection after clinical. Transplantation as a potent immunosuppressant [8]. Later, Cs-A has been regarded as an immunoregulatory and anti-inflammatory drug for the treatment of various. Immune inflammatory diseases, such as Bechet’s syndrome [9] and atopic
keratoconjunctivitis[10]. Moreover, a few studies show that Cs-A has a protective effect on the retina of streptozotocin (STZ)-induced diabetic rats, possibly through impeding the immunoglobulins deposition[11] or reducing the blood-retinal barrier permeability[12] in the diabetic retina. However, little has been known about the impact of Cs-A on the retina of type 2 diabetic rats and the underlying mechanism. Therefore, the aim of our study was to investigate the effect of Cs-A on the retinopathy in a type 2 DM animal model and to elucidate its potential mechanism, specifically, to study the alternation of expression levels of HMGB-1, IL-1β and TNF-α in the retinal tissues.

Methods

Animals
Healthy male Sprague-Dawley rats (n = 64, aged 8–10 weeks, weighed between 200 and 250 g) were used for all experiments. All rats were purchased from the Experimental Animal Center of Chongqing Medical University, where rats were housed in cages on a 12-h light-dark schedule with food and water ad libitum. All procedures were performed in accordance to the Chongqing Medical University’s Animal Care and Use Committee Guidelines.

Induction of type 2 diabetes mellitus
After 1 week of adaptive feeding, 40 rats were randomly divided into two groups: Normal group and Diabetic group. Rats in the Normal group were fed with normal chow diet, while those in the DM group with a high-fat and high-glucose diet. Four weeks later, streptozotocin (STZ; Sigma-Aldrich) was prepared in acetate buffer and administered (30 mg/kg) via intraperitoneal injections for 5 consecutive days at 7–9 weeks of age. Normal group mice were administered an intraperitoneal injection of acetate buffer (pH 4.5). After injection, blood glucose level greater than 16.7 mmol/L was taken as the successful establishment of type 2 DM model. After successful diabetes induction, rats were treated according to the study design. At the end of the treatment, animals were sacrificed with overdose pentobarbital. Rat eyeballs were enucleated and immediately put into 40 g/L paraformaldehyde for hematoxylin and eosin (H-E) staining or immunohistochemistry. Retinas were isolated carefully and snap frozen in liquid nitrogen for western blot or enzyme-linked immunosorbent assay (ELISA).

Intravitreal treatment of Cs-a/HMGB-1
This study comprised of two experimental parts. First, rats in the Normal and DM group were deeply anesthetized by pentobarbital injection, and topical ocular anesthesia was achieved with 0.4% benoxinate hydrochloride of eye drop. After pupils were dilated satisfactorily, rats were injected with Cs-A (42 ng/2 μL Dimethyl sulfoxide (DMSO)) intravitreally in the left eye with a 30-gauge micro-injector under a dissecting microscope. For the control, 2 μL DMSO was injected into the right eye of the same rat. According to the treatment, rat eyes could be categorized into four groups: Normal, Normal+Cs-A, DM and DM + Cs-A group. Rats with operational complications such as vitreous hemorrhage, retinal detachment or death were excluded from our study. Forty-eight hours after administration of Cs-A, rats were anesthetized and sacrificed for further experiments.

The second part of the experiment was that twenty-four normal healthy rats. (Sprague-Dawley, non-diabetic, 200–250 g) were subjected to intravitreal injections into the left eyes using the method described above. Rats were divided into three groups according to the injection substances: Normal control group (n = 8) received 5 μL sterile phosphate buffer saline (PBS); Normal+HMGB-1 group (n = 8) received sterilized solution of recombinant HMGB-1 (5 ng/5 μL PBS; R&D Systems, Minneapolis, MN); and Normal+HMGB-1 + Cs-A group (n = 8) received a combination of HMGB-1(5 ng/5 μL PBS) and Cs-A (42 ng/2 μL DMSO).

H-E staining of the retinal tissues
Rat eyeballs were dehydrated using graded ethanol and embedded in paraffin. Sections of five-micron thickness were cut and transferred to triethoxyxilane-coated slides. The tissues were stained with hematoxylin–eosin and examined for morphometry. Images were taken through an Olympus BX60 microscope (Olympus Optical Co Ltd., Tokyo, Japan).

Immunohistochemistry and Western blot
For immunohistochemistry, the paraffin-embedded retinal sections (5 μm) were dewaxed and dehydrated. Endogenous peroxidase was quenched with 3% H2O2 blocker for 10 min at room temperature. Then, the sections were incubated with anti-HMGB-1 antibody (1:500, Epitomics, Cambridge, U.K.) at 4 °C overnight. After extensive washing with PBS, the sections were incubated with horseradish peroxidase-streptavidin immunoglobulin (1:500, Abcam, Cambridge, UK) for 30 min, developed with diaminobenzidine for 3 min and counterstained with hematoxylin. Quantitative image analysis was performed with Image-Pro Plus 6.0 software (Media Cybernetics Inc., Bethesda, Maryland MD, USA). Ten fields per retina were randomly selected and the densitometry mean values of HMGB-1 immunostaining were determined.

For western blot, protein extracts were collected with a tissue lysis buffer (PBS containing 10 mM EDTA, 1% Triton X-100 and the protease inhibitor cocktail) and the concentrations were determined using a bicinchoninic acid protein assay kit (Bio-Rad, Richmond, CA). Protein samples were separated on polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride
membrane. The membrane was blocked with 5% dry milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h. Primary antibodies were incubated at 4 °C overnight at the following dilutions: anti-HMGB-1 antibody (1:500, Epitomics, Cambridge, U.K.), anti-IL-1β antibody (1:500, Epitomics, Cambridge, U.K.), anti-TNF-α antibody (1:500, Abcam, Cambridge, U.K.) or anti-actin antibody (1:1000, Sigma, St. Louis, MO, USA), and then incubated with secondary hors eradish peroxidase-conjugated antibody (1:1000, Abcam, Cambridge, U.K.) for 1 h at 37 °C. The immunocomplexes were visualized by the ECL chemiluminescence method. Subsequently, semi-quantitative analysis was performed using the quantity one software (Bio-Rad, Richmond, CA). The amount of target proteins was quantified relative to the level of β-actin.

**ELISA assay of IL-1β and TNF-α**
At the end of the treatment, each retina was dissected and homogenized in 100 μL of lysis buffer supplemented with protease inhibitors (Beyotime). Samples were centrifuged at a speed of 12,000 rpm for 10 min at 4 °C and the supernatants were collected. After protein concentrations were assessed with the Bio-Rad method (Bio-Rad, Richmond, CA), samples were subjected to corresponding ELISA kits (R&D Systems, Minneapolis, MN) for the determination of IL-1β and TNF-α levels according to the manufacturer’s instructions. The absorbance at 450 nm was read on an automated plate reader (Spectra Max Gemini UVmax; Molecular Devices, Sunnyvale, CA). All measurements were performed in triplicate and the tissue sample concentration was calculated from a standard curve and corrected for protein concentration.

**RNA extraction and RT-PCR**
The retinas were separated from eyeballs. Total RNA was extracted from mouse retinal tissues using a RNAiso kit (Invitrogen, Paisley, UK) according to the manufacturer’s instructions. Reverse transcription was carried out on the extracted total RNA by a reverse transcription kit (Mbi, Glen Burnie, MD, USA) to obtain cDNA, and the operation steps were carried out according to the reverse transcription kit manufacturer’s instructions. Amplification was carried out by SYBR Green kit (Roche Diagnostics, Basel, Switzerland), and IL-1β primer, TNF-α primer and GAPDH primer were synthesized and designed by Shanghai Sangon Biological Engineering Technology & Services Corporation. More details are shown in Table 1. The PCR amplification conditions were as follows: pre-incubation for 5 min at 94 °C, 35 cycles of amplification (94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s). Both IL-1β and TNF-α were normalized to GAPDH expression using the 2^ΔΔCt method.

**Statistical analysis**
The data were expressed as mean ± standard deviation (SD). Data were analyzed using the one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test. All statistical analyses were performed with GraphPad Prism software (version 4.0, GraphPad Software, San Diego, Calif.). *P* value less than 0.05 was considered statistically significant.

**Results**

**Animal characteristics**
At the end of the experiment period, the fasting blood glucose levels of rats in the DM group were significantly higher than those in the Normal group (16.81 ± 3.14 vs. 5.04 ± 0.48 mmol/L, *p < 0.01*). However, there was no significant difference in fasting blood glucose levels between DM and DM + Cs-A group (16.81 ± 3.14 vs. 15.04 ± 4.28 mmol/L), Normal and Normal +Cs-A group (5.04 ± 0.48 vs. 5.81 ± 0.73 mmol/L), respectively.

**The pathomorphological changes of retinal tissues**
Retinal tissues with HE staining showed no remarkable retinal abnormalities in the Normal and Normal +Cs-A group, as retinal cells were well-shaped and organically-aligned in each layer of the retinal tissues (Fig. 1a and b). In the DM group, there was presence of thickening and edema in the retinal ganglion cell layer, inner plexiform layer, and outer nuclear layer, with disordered retinal cell arrangements especially in the inner nuclear layer and outer nuclear layer (Fig. 1c). On the contrary, abnormalities of cell edema and disarrangement were obviously attenuated in the DM + Cs-A group (Fig. 1d).

**Immunohistochemical detection and the protein expression of HMGB-1**
Location and expression level of HMGB-1 in the retinal tissues were determined by immunohistochemistry and western blot methods. The levels of immunostaining to HMGB-1 in retinas were significantly higher in the diabetic rats than in the normal ones (Fig. 2a and c), and Cs-A treatment significantly reduced this effect induced

| Table 1: Primer sequence |
|--------------------------|
| **Gene** | **Upstream primer** | **Downstream primer** |
| IL-1β | 3’-TGGAATGAGGATGACTGTG-5’ | 3’-TGTTGCTGAGGATTCGTA-5’ |
| TNF-α | 3’-GAGCAGATGCGATCC-5’ | 3’-CGAGAAGATGATCTGACT-5’ |
| GAPDH | 3’-CTAGAAGCTAGAAGACG-5’ | 3’-GATAGTCGCCAAGCATGG-5’ |
Fig. 1 Photomicrographs of rat retinas with H-E staining: (a) Normal group: retinal cells displayed normal shapes and orderly arrangements in every layer of the retinal tissues; (b) Normal + Cs-A group: no obvious abnormalities were observed compared to the normal group; (c) DM group: there were edema and thickening of ganglion cell layer, inner plexiform layer and outer nuclear layer, besides disordered alignments of inner nuclear layer; (d) DM + Cs-A group: there were approximately regular arrangements of retinal cells and slightly thickened retina tissues. Original magnification was 400X.

Fig. 2 Immunohistochemical detection and the protein expression of HMGB-1 (a) Normal group (b) Normal + Cs-A group (c) DM group and (d) DM + Cs-A group. Original magnification was 400X. Semiquantitative analyses of HMGB-1 levels were shown in (e). Data are mean ± SD, **p < 0.01 vs. Normal group and Normal + Cs-A group, and ※※p < 0.01 vs. DM group. (f) The expression HMGB-1 protein in Normal, Normal + Cs-A, DM and DM + Cs-A group respectively. (g) Mean ± SD of HMGB-1 protein level normalized to β-actin (internal control) were calculated. **p < 0.01 vs. Normal group and Normal + Cs-A group, and ※※p < 0.01 vs. DM group.
by diabetes (Fig. 2d). However, Cs-A treatment had no obvious effect on HMGB-1 expression in the retinas of normal rats (Fig. 2a and b).

Retinal HMGB-1 protein expression was significantly higher in the diabetic rats than in the normal ones (Fig. 2f), and Cs-A treatment significantly reduced this effect induced by diabetes (Fig. 2fa and g).

Retinal protein and mRNA expressions of IL-1β and TNF-α with Cs-a treatment
Compared with the Normal group, retinal protein and mRNA expression of IL-1β in the DM and DM + Cs-A group increased significantly (p < 0.01). However, the expression level of IL-1β in the DM + Cs-A group was significantly lower than that in the DM group (p < 0.01). There was no significant difference between the Normal and Normal + Cs-A group in retinal IL-1β expression (Fig. 3a and c). Similar trends were observed in the retinal protein expression of TNF-α (Fig. 3b and d).

Retinal protein expressions of IL-1β and TNF-α with HMGB-1 treatment
Compared with the Normal control group, retinal protein expression of IL-1β and TNF-α in the Normal+HMGB-1 group and Normal+HMGB-1+ Cs-A group increased significantly (p < 0.01, respectively). However, the expression levels of IL-1β and TNF-α in the Normal+HMGB-1 + Cs-A group was significantly lower than that in the Normal+HMGB-1 group (p < 0.01, respectively) (Fig. 4).

Discussion
Previously we have demonstrated that Cs-A has a protective effect on the structure and function of retina in rats with STZ-induced DM [13]. In the present study, we showed that Cs-A could attenuate retinal edema in diabetes-caused retinopathy, using a well-established animal model of type 2 DM by administration of a high-fat and high-glucose diet combined with a small dose of STZ injection [14]. In addition, the effect of Cs-A could be possibly attributed to the decreased expression levels of HMGB-1 and relating inflammatory mediators (IL-1β and TNF-α) in the retina. In the past decades, increasing studies have indicated that inflammation play a key role in the pathogenesis of diabetic retinopathy [3, 15–17]. There are many features typical of inflammation in the retina of diabetic patients and rodents, such as increased blood flow and vascular permeability [17], enhanced leukocyte adhesion and macrophage infiltration [18, 19], and strengthened expression of various inflammatory mediators [15, 20]. Many of those mediators have become research spots as they may stand as potential therapeutic targets for the treatment of diabetic retinopathy, IL-1β and TNF-α should be counted. The two cytokines have caused special attention for that they contribute to the development of retinopathy as well as provide neurotrophic functions to support retinal cell survival [21].

Demircan et al. [22] found that expression levels of IL-1β and TNF-α were increased in the vitreous humor and
serum of patients with proliferative diabetic retinopathy. Kowluru et al. [23] and Behl et al. [24] documented that diabetes enhanced the production of IL-1β and TNF-α in the rat retina, respectively. More importantly, drug inhibition of IL-1β or gene knockout of the receptor for IL-1β significantly prevented the degeneration of retinal capillaries caused by diabetes [25]. Specific inhibitor or genetic deficiency of TNF-α greatly reduced the leukocyte adhesion and blood-retinal barrier breakdown in the diabetic retina [5, 24]. In agreement with these studies, we demonstrated a significant upregulation of IL-1β and TNF-α in the six-week diabetic rat retina, and that intravitreal administration of Cs-A significantly decreased this upregulation induced by diabetes.

Cs-A binds to cyclophilin A, forming a drug protein complex, which blocks calcineurin (Ca2+/calmodulin-dependent protein phosphatase), and subsequently leads to the downregulation of numerous proinflammatory factors such as IL-1β and TNF-α [26]. In our study, Cs-A exerted anti-inflammatory and inhibitory effect on retinopathy in the diabetic retina via reducing the retinal levels of IL-1β and TNF-α. This result agrees with previous study reporting that Cs-A inhibits the in vivo synthesis of IL-1β and TNF-α in some thymic mice [27]. Similarly, an inhibitory effect of Cs-A was showed in vitro, for instance, in rat renal mesangial cells and in unseparated peripheral blood mononuclear cells [28, 29].

In the present study, increased HMGB-1 immunoreactivity was observed in the retina of type 2 diabetic rats compared to the normal rats. HMGB-1, originally identified as a non-histone chromatin-binding protein [30] can be released into the extracellular space either passively or actively as a signal to trigger inflammation [31]. Extracellular HMGB-1 may signal via the receptor for advanced glycation end products (RAGE) and toll-like receptors 2 and 4. Activation of these receptors results in the activation of nuclear transcription factor Kappa B (NF-κB), which accelerates the production of cytokines such as IL-1β and TNF-α, thereby promoting inflammation [16]. Under diabetic environment, HMGB-1 acts as a proinflammatory cytokine participating in the pathogenesis of diabetic retinopathy [6].

Moreover, Mohammad et al. [7] showed that intravitreal administration of HMGB-1 to normal rats caused “diabetic-like” retinopathy, which could be greatly relieved by a specific inhibitor of HMGB-1 (Glycyrrhizin). Consistently, we proved that intravitreal injection of HMGB-1 to normal rats upregulated the retinal levels of inflammatory mediators namely IL-1β and TNF-α, and the effect was significantly attenuated by Cs-A treatment. Our results are consistent with the in vitro study reported by Gabryel et al., which provides evidence that Cs-A decreases HMGB-1 expression in ischemic astrocytes and thus attenuates the ischemia induced necrosis and neuroinflammation [32]. Noteworthy in the present study, Cs-A did dramatically extend but not extinguish the adverse effect of diabetes or HMGB-1 on the rat retina. Inadequate concentration of Cs-A may be counted as a reason. Since we have previously demonstrated that Cs-A of 42 ng/2 μl were effective to ease retinopathy in STZ-induced diabetic rats [13], the type 2 diabetic rat model used in our study may also, be taken into consideration.

**Conclusions**

In summary, this study shows that protein expressions of IL-1β and TNF-α were enhanced in the retina of diabetic rats and the Cs-A treatment was able to attenuate the enhancement, possibly via the suppression of HMGB-1. Altogether, these results indicate that intravitreal injection of Cs-A may represent a novel therapeutic strategy for the treatment of diabetic retinopathy. However, further studies are warranted to elucidate the molecular mechanism underlying the protective effect of Cs-A on diabetic retina.
Abbreviations
Cs-A: Cyclosporine-a; DM: Diabetes mellitus; DMSO: Dimethyl sulfoxide; DR: Diabetic retinopathy; HMGB-1: High mobility group box-1; PBS: Phosphate buffer saline; RAGE: Receptor for advanced glycation end products; TNF-α: Tumor necrosis factor-α

Acknowledgments
Not applicable.

Authors’ contributions
PW and FC were involved in experimental designs and drafting the manuscript. PW and FC were involved in Methodology. XZ was involved in Writing-review & editing and Supervision. All authors read and approved the final version of the manuscript.

Funding
This work was supported by the fund projects of the National Natural Science Foundation of China (81870673).

Availability of data and materials
All data generated or analyzed during the present study are included in this published article. More details are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All experiments were performed in accordance with the international guidelines Principles of Laboratory Animals Care and were approved by the Animal Care Committee of Chongqing Medical University.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Received: 16 August 2019 Accepted: 21 January 2020

Published online: 04 February 2020

References
1. Fong Donald S, Lloyd A, Gardner Thomas W, King George L, George B, et al. Retinopathy in diabetes. Diabetes Care. 2004;27:94–7.
2. Sarah W, Gojka R, Anders G, Richard S, Hilary K. Global. prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
3. Adams AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2003;86:623–5.
4. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147–52.
5. Joussen Antonia M, Vassiliki P, Nicholas M, Bermd K, Kan K, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438–40.
6. Abu E-AAM, Imtiaz NM, Dusan K, Karel G, Shamshul OM, et al. Highmobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011;17:1829–38.
7. Ghulam M, Mairaj SM, Amini O, Mohamed A-S, Abu El-Atrash Ahmed M. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2013;107:101–9.
8. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 1984;101:667–82.
9. Haterni G, Seyali E, Fresko I, Hamuryudan V. Behcet's syndrome: a critical. digest of the recent literature. Clin Exp Rheumatol. 2012;30:80–9.
10. González-López Julio J, Jesús L-A, Rafael ML, Roberto FB, Gema RF. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev. 2012;9:CD009078.
11. Xin Z, Jin C, Ming-cai Q, De-qiang L, Peng Z, et al. The effects of cyclosporine-A on immunoglobulins deposition in retina of streptozotocin-induced diabetic rats. Zhonghua Nei Ke Za Zhi. 2008;47(2):125–8.
12. Camo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Effect of cyclosporin-A on the blood–retinal barrier permeability in streptozotocin-induced diabetes. Mediat Inflamm. 2000;9:243–8.
13. Yuan-juan Z, Shen Q, Xue-dong Z, Bo L, Yan-hong F, et al. The protective effects on the function and structure of retinae in diabetic rats by intravitreal injection of cyclosporin A. Zhonghua Yan Ke Za Zhi. 2012;48:591–7.
14. Srinivasan K, Viswanad B, Lyda A, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52:313–20.
15. Joussen Antonia M, Vassiliki P, Ly LM, Kan K, Christia E, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18:1450–2.
16. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–58.
17. Antonetti David A, Barber Alistair J, Bronson Sarah K, Freeman Willard M, Gardner Thomas W, et al. Diabetic retinopathy: seeing beyond glucose-induced. Microvasc Dis. Diab. 2006;52:2401–11.
18. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U A. 1999;96:10386–41.
19. Eszer P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77:731–3.
20. Hatice C, Iltu V, Ozcan Atan A, Abdullah C, Doran F, et al. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition, of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2005;13:375–81.
21. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nat. 2005;438:960–6.
22. Demircan N, Safran BG, Soylu M, Ozcan AA, Szamaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:366–9.
23. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol. 2004;88:1343–7.
24. Yugal B, Padmaja K, Tesfahun D, Amanda DP, Sayon R, et al. Diabetes-enhanced tumor necrosis factor alpha production promotes, apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008;172:1411–8.
25. Vincent JA, Heimann K, Wiedemann P. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal ganglion cells in diabetes and galactosemia. Diab. 2007;56:224–30.
26. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109:67–9.
27. Dawson J, Kurtenbach U, MacKenzie A. Cyclosporin A inhibits the in vivo production of interleukin-1beta and tumour necrosis factor alpha, but not interleukin-6, by a T-cell-independent mechanism. Cytochrome. 1996;8:882–8.
28. Konz D, Walter G, Eberhardt W, Nitsch D, Pfeilschifter J. Interleukin 1 beta-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. Biochim Biophys Acta. 1995;12648–46.
29. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med. 1987;166:571–6.
30. Einck L, Bustin M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res. 1985;156:295–310.
31. Raucci A, Palumbo R, Bianchi MC. HMGB1: a signal of necrosis. Autoimmun Rev. 2005;8:82.
32. Haterni G, Seyali E, Fresko I, Hamuryudan V. Behcet’s syndrome: a critical. digest of the recent literature. Clin Exp Rheumatol. 2012;30:80–9.
33. Gonzalez-Lopez Julio J, Jesus L-A, Rafael ML, Roberto FB, Gema RF. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev. 2012;9:CD009078.
34. Xin Z, Jin C, Ming-cai Q, De-qiang L, Peng Z, et al. The effects of cyclosporine-A on immunoglobulins deposition in retina of streptozotocin-induced diabetic rats. Zhonghua Nei Ke Za Zhi. 2008;47(2):125–8.
35. Raucci A, Palumbo R, Bianchi MC. HMGB1: a signal of necrosis. Autoimmun Rev. 2005;8:82.
36. Bozina G, Anisa B, Jacek B, Krysztof L, Herman Zbigniew S. Immunosuppressant cytoprotection correlates with HMGB1 suppression in primary astrocyte cultures exposed to combined oxygen-glucose deprivation. Pharmacol Rep. 2011;63:392–402.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.